301 related articles for article (PubMed ID: 24559439)
1. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
2. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Sharp A; Welti J; Blagg J; de Bono JS
Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
[TBL] [Abstract][Full Text] [Related]
3. Galeterone activity in castration-resistant prostate cancer.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
[No Abstract] [Full Text] [Related]
4. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
Martinez-Ariza G; Hulme C
Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
[TBL] [Abstract][Full Text] [Related]
6. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
8. The biology of castration-resistant prostate cancer.
Lian F; Sharma NV; Moran JD; Moreno CS
Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
[No Abstract] [Full Text] [Related]
9. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
10. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
11. [Sequential therapy for castration-resistant prostate cancer].
Nozawa M; Uemura H
Nihon Rinsho; 2016 May; 74 Suppl 3():644-8. PubMed ID: 27344809
[No Abstract] [Full Text] [Related]
12. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
13. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
Ge R; Xu X; Xu P; Li L; Li Z; Bian J
Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
Quintela ML; Mateos LL; Estévez SV; Calvo OF; Herranz UA; Afonso FJ; Santomé L; Aparicio LA
Cancer Treat Rev; 2015 Mar; 41(3):247-53. PubMed ID: 25638257
[TBL] [Abstract][Full Text] [Related]
16. Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.
Alva A; Hussain M
Drugs; 2013 Sep; 73(14):1517-24. PubMed ID: 23959841
[TBL] [Abstract][Full Text] [Related]
17. Targeting continued androgen receptor signaling in prostate cancer.
Massard C; Fizazi K
Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
[TBL] [Abstract][Full Text] [Related]
18. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
19. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Guo C; Sharp A; Gurel B; Crespo M; Figueiredo I; Jain S; Vogl U; Rekowski J; Rouhifard M; Gallagher L; Yuan W; Carreira S; Chandran K; Paschalis A; Colombo I; Stathis A; Bertan C; Seed G; Goodall J; Raynaud F; Ruddle R; Swales KE; Malia J; Bogdan D; Tiu C; Caldwell R; Aversa C; Ferreira A; Neeb A; Tunariu N; Westaby D; Carmichael J; Fenor de la Maza MD; Yap C; Matthews R; Badham H; Prout T; Turner A; Parmar M; Tovey H; Riisnaes R; Flohr P; Gil J; Waugh D; Decordova S; Schlag A; Calì B; Alimonti A; de Bono JS
Nature; 2023 Nov; 623(7989):1053-1061. PubMed ID: 37844613
[TBL] [Abstract][Full Text] [Related]
20. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
Kim W; Ryan CJ
Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
